049960 — Cell Biotech Co Balance Sheet
0.000.00%
- KR₩91bn
- KR₩3bn
- KR₩50bn
- 81
- 85
- 65
- 93
Annual balance sheet for Cell Biotech Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 54,887 | 57,834 | 65,368 | 70,332 | 87,454 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 5,826 | 5,217 | 5,336 | 6,397 | 4,980 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 64,913 | 67,519 | 75,655 | 81,929 | 97,148 |
| Net Property, Plant And Equipment | 36,602 | 34,057 | 33,638 | 32,937 | 30,463 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 105,301 | 112,877 | 115,839 | 117,641 | 130,398 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 4,630 | 5,766 | 7,389 | 4,821 | 5,863 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 5,317 | 6,189 | 7,747 | 5,755 | 6,229 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 99,985 | 106,687 | 108,092 | 111,885 | 124,168 |
| Total Liabilities & Shareholders' Equity | 105,301 | 112,877 | 115,839 | 117,641 | 130,398 |
| Total Common Shares Outstanding |